
Axsome Therapeutics, Inc.: updates and filings
Price
$129.36
November 20, 2026Market cap $6.6B
What Ploutos Investor adds for Axsome Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 2, 2026next Feb 3, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 2, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 2, 2026Results of operations, other material eventsForm8-K
- Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 10, 2026Results of operations, other material eventsForm8-K
- Jul 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 15, 2026Other material eventsForm8-K
- Jun 9, 2026Officer or director changeForm8-K
- Jun 9, 2026Shareholder voteForm8-K
- Jun 3, 2026Other material eventsForm8-K
- May 5, 2026Filing (amendment)Form144/A
- May 4, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 4, 2026Results of operations, other material eventsForm8-K
- Apr 30, 2026Other material eventsForm8-K
- Apr 24, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 24, 2026Additional annual meeting materialFormDEFA14A
- Apr 24, 2026Annual meeting proxy statementFormDEF 14A
- Apr 1, 2026Other material eventsForm8-K
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 23, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 23, 2026Results of operationsForm8-K
- Feb 17, 2026Other material eventsForm8-K
- Jan 12, 2026Results of operations, other material eventsForm8-K
- Dec 31, 2025Other material eventsForm8-K
- Nov 3, 2025Shelf registration for future offeringsFormS-3ASR
- Nov 3, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 2, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 2, 2026 | 8-K | Results of operations, other material events | Document |
| Aug 10, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 10, 2026 | 8-K | Results of operations, other material events | Document |
| Jul 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 15, 2026 | 8-K | Other material events | Document |
| Jun 9, 2026 | 8-K | Officer or director change | Document |
| Jun 9, 2026 | 8-K | Shareholder vote | Document |
| Jun 3, 2026 | 8-K | Other material events | Document |
| May 5, 2026 | 144/A | Filing (amendment) | Document |
| May 4, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 4, 2026 | 8-K | Results of operations, other material events | Document |
| Apr 30, 2026 | 8-K | Other material events | Document |
| Apr 24, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 24, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 24, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 1, 2026 | 8-K | Other material events | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 23, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 23, 2026 | 8-K | Results of operations | Document |
| Feb 17, 2026 | 8-K | Other material events | Document |
| Jan 12, 2026 | 8-K | Results of operations, other material events | Document |
| Dec 31, 2025 | 8-K | Other material events | Document |
| Nov 3, 2025 | S-3ASR | Shelf registration for future offerings | Document |
| Nov 3, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 19, 2013.
The full analysis
What do Axsome Therapeutics's filings show?
The filings are where every one of Axsome Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.